stockrowBioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.
- Revenue
- −16.4%
- EPS
- +708.4%
- Free cash flow
- −123.8%
- Total debt
- +44.4%
Quarter to September 2026, against a year earlier
Follow BNTX
Alert me
BioNTech SE Sponsored ADR (BNTX) Total debt
BioNTech SE Sponsored ADR's total debt at the end of fiscal 2025 was $302.5M, up 9.99% from $275.1M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $414.1M. Over the past ten years it has ranged from $62.0M (fiscal 2017) to $356.7M (fiscal 2021); the current reading is higher than 89% of that period. BioNTech SE Sponsored ADR ranks 31st of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $302.5M | 9.99% |
| FY2024 | $275.1M | 16.00% |
| FY2023 | $237.1M | 6.06% |
| FY2022 | $223.6M | (37.32%) |
| FY2021 | $356.7M | 30.01% |
| FY2020 | $274.4M | 247.12% |
| FY2019 | $79.0M | 23.50% |
| FY2018 | $64.0M | 3.23% |
| FY2017 | $62.0M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $414.1M | 12.68% |
| Jun 2026 | $367.5M | 3.71% |
| Mar 2026 | $354.4M | 17.14% |
| Dec 2025 | $302.5M | 5.47% |
| 23 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| GMAB Genmab A/S Sponsored ADR compare | $5.1B |
| BBIO BridgeBio Pharma, Inc. compare | $1.9B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $1.0B |
| INSM Insmed, Inc. compare | $562.8M |
| ASND Ascendis Pharma A/S compare | $523.3M |
| BNTX BioNTech SE Sponsored ADR | $414.1M |
| ROIV Roivant Sciences Ltd. compare | $323.7M |
| EXEL Exelixis, Inc. compare | $191.0M |
| INCY Incyte Corporation compare | $27.6M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on BNTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement